Peptide record

TPDB91242

C1Triazole ACE inhibitors Anticancer Antioxidant modified_plain modified
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91242
C1Triazole
ACE inhibitors Anticancer Antioxidant
Cardiometabolic peptides Cancer-related peptides Functional / health-promoting peptides
Peptipedia CancerPPD 2.0 dbACP AnOxPePred - 1.0 AODB AoXpDb Multi-AOP
modified_plain
Yes
A 5-aa modified multi-activity (ACE inhibitors, Anticancer, and Antioxidant) peptide sequence curated from Peptipedia, CancerPPD 2.0, dbACP, and other sources, with an available 3D structural model.
N-terminal: 4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid
Sequence
GLTSK
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
5 reviewed residue count
Free Activity
L Activity
Linear Activity
4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid Activity
Anticancer Activity
Synthetic Activity
Evidence Records 3 records
Evidence 1 Activity

Activity

59.76 ± 10.34 inhibition % at 10 µM
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

79.9 ± 0.49 inhibition % at 10 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 3 Activity

Activity

92.8 ± 0.16 inhibition % at 10 µM
Anticancer

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019